Status of Alzheimer’s research

Alzheimer; News from the web:

There are roughly 326 active, recruiting or enrolling by invitation clinical trials on the elusive disease, per clinicaltrial.gov. The U.S. last year dramatically stepped up funding for Alzheimer’s disease research, from $400 million a year to over $2 billion annually, although the Alzheimer’s Association says more is needed.

The biggest problem: Scientists still don’t know the cause of Alzheimer’s.

Read all about it HERE

Failed trial

Alzheimer; News from the web:

The companies developing aducanumab, Biogen and its partner Eisai, announced that they halted two late-stage trials of the experimental drug after an independent group’s analysis showed that the trials were unlikely to “meet their primary endpoint.”

The Cambridge, Massachusetts-based biotech giant joins a long list of companies in the last decade that have failed to find a treatment for Alzheimer’s.

Read all about it HERE

The end to senior moments near?

Alzheimer; News from the web:

A new drug shows promising results: Early results indicate that the drug could reverse natural, age-related cognitive decline. Researchers also believe that it might help patients whose memories are impaired because of conditions such as depression, schizophrenia and Alzheimer’s disease.

Read all about it HERE

Will we ever find a cure?

Alzheimer; News from the web:

The New York Times has a great article today, read it in our link below.

“The field is desperate, and we all want something to work,” said Dr. Reisa Sperling, director of the Center for Alzheimer Research and Treatment at Brigham and Women’s Hospital in Boston.

Read all about it HERE

(our blog will be on a short break to celebrate the US Thanksgiving, back on Monday)

New research promising for prevention of cognitive decline

Alzheimer; News from the web:

A new study from The University of Texas Medical Branch at Galveston has provided researchers important insights about an enzyme within the brain that plays a critical role in Alzheimer’s.

The UTMB researchers found that blocking the enzyme helped prevent memory loss in mice.

The enzyme is a promising target for developing medications to prevent cognitive decline. The study was recently published in Alzheimer’s and Dementia: Translational Research and Clinical Interventions.

Read all about it HERE

Brain muddled after surgery? Now we know why.

Alzheimer; News from the web:

It has been known that people can be disoriented after general anesthesia but now a study found that propofol (a very common drug to use) also disrupts presynaptic mechanisms, probably affecting communication between neurons across the entire brain in a systematic way that differs from just being asleep. In this way it is very different than a sleeping pill

Read all about it HERE

Another promising Alzheimer’s drug

Alzheimer; News from the web:

In a new study, a Salk team found that J147 binds to a protein called ATP synthase, which is responsible for producing a common cellular “energy currency” known as ATP. This protein is known to control aging in worms and flies, and the researchers found that by binding to it the drug was able to prevent age-related damage to the brain.

Read all about it HERE

I want to believe this

Alzheimer; News from the web:

Novel Drug Shows Promising Results in Alzheimer’s Model

  • Scientists report that a novel small-molecule drug, which works by stopping toxic ion flow in the brain that is known to trigger neuronal apoptosis, can restore brain function and memory in a mouse model of Alzheimer’s disease (AD). The team believes the drug could be used to treat AD and other neurodegenerative diseases such as Parkinson’s and amyotropic lateral sclerosis (ALS).

Read all about it HERE

Patent law an obstacle for Alzheimer’s solutions

Alzheimer; News from the web:

You would think that all would be working cooperatively towards a solution for Alzheimer’s but this is not the case. The ridiculous costs and time that it takes to run effective tests lead to a short time to recoup your research costs when you would find a workable solution. Researchers can not make a good case that this is a wise investment for Pharmaceutical companies.

So something is really wrong here and the government should look into this.

Read all about it HERE

Israeli researchers may have found a trigger!

Alzheimer; News from the web:

Dr. Debbie Toiber, of the BGU Department of Life Sciences, and her team discovered that a specific protein — Sirtuin-6 (SIRT6) — is severely reduced in the brains of Alzheimer’s patients. SIRT6 is critical to the repair of DNA, the deterioration of which “is the beginning of the chain that ends in neurodegenerative diseases in seniors,” she explains.

The blood-brain barrier prevents us from simply being able to inject the protein into the brain to replenish its supply. Dr. Toiber is currently working on finding a way to increase the expression of the protein into the brain.

Read all about it HERE